Allergan gets exclusive rights to Merck's CGRP program for migraine
Merck & Co. Inc. granted Allergan PLC exclusive global rights to its small-molecule oral calcitonin gene-related peptide (CGRP) program for migraine drug development.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.